Ayu Life Sciences is setting up a AED 33 million (US$9 million) advanced manufacturing facility in Dubai’s Jebel Ali Free Zone (Jafza), marking a regional first for high-tech wound care and surgical treatments.
Spanning 13,500 square metres, the new site will produce next-generation medical solutions, including artificial skin and antimicrobial dressings, aimed at meeting surging global demand for sustainable healthcare products. Phase 1 of the project is scheduled to be operational by late 2025, with full completion expected by 2027.
The facility will manufacture Ayu Life Sciences’ key products: Velgraft™, a skin substitute for scar-free healing; Velvert™, a wound care dressing that prevents infection; and VelNez™, a post-surgical nasal and ear dressing. These products are backed by 22 global patents and developed using eco-friendly, natural materials.
The move comes as the artificial skin market is projected to grow from US$3.1 billion in 2024 to US$5.3 billion by 2032. Ayu Life Sciences currently exports to over 20 countries from its Delhi base, serving some of the world’s most tightly regulated healthcare markets.
The company is also advancing research in regenerative medicine, with clinical trials underway for a potential Type 1 diabetes therapy and a treatment for peripheral nerve injuries.
Dr. Rajan Datt, Managing Director of Ayu Life Sciences, called the Jafza expansion a “major milestone,” highlighting Dubai’s strategic value in scaling access to innovative care across the Middle East and beyond.
Abdulla Al Hashmi, COO of Parks & Zones at DP World GCC, noted that the move underscores Dubai’s growing role in advanced medical manufacturing and reinforces Jafza’s position as a launchpad for global healthcare innovation.
News Source: Dubai Media Office
